Somaxon Pharmaceuticals
Recent developments from Somaxon Pharmaceuticals summarized
Published in Health Business Week, March 9th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Somaxon Pharmaceuticals.
Report 1: Somaxon Pharmaceuticals, Inc. (SOMX) announced results from the company's phase 2/3 clinical trial evaluating 20 mg and 40 mg of oral nalmefene hydrochloride, an opiate antagonist, in patients with a diagnosis of pathological gambling.
Nalmefene did not demonstrate a statistically significant difference compared to placebo on the primary endpoint, mean PG-YBOCS (Yale Brown Obsessive Compulsive Scale modified for Pathological Gambling)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-03-09)
More Articles from Health Business Week
- AARP
AARP CEO Sets Association Priorities That Promote Health and Long-term Financial Security - Abbott
Abbott Announces 10.2 Percent Increase in Quarterly Dividend - Accellion, Inc.
FoxHollow Technologies Selects Accellion's Secure File Transfer Solution to Send Large Files without Email Server Complications - Acne Vulgaris
AndroScience Corporation Enters Clinical Stage - Actavis Group
Actavis Launches Alprazolam ER Tablets in the U.S. - Acusphere, Inc.
Acusphere to Present at Susquehanna Financial Group's Significant Investment Options in Healthcare Conference - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
